NCT00687362View on ClinicalTrials.gov

A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 30, 2006

Primary Completion Date

November 11, 2008

Study Completion Date

November 11, 2008

Conditions
Psoriasis
Interventions
BIOLOGICAL

Infliximab

Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00687362 - A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528) | Biotech Hunter | Biotech Hunter